|
Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). |
|
|
Honoraria - Exelixis; Genentech/Roche; Ignyta |
Consulting or Advisory Role - AstraZeneca; Exelixis; Genentech/Roche |
Speakers' Bureau - Ignyta |
Research Funding - Foundation Medicine |
Travel, Accommodations, Expenses - AstraZeneca; Exelixis; Genentech/Roche; Ignyta |
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - EPharma |
Research Funding - Pfizer (Inst) |
|
|
|
Consulting or Advisory Role - Genentech |
Research Funding - Pfizer (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Biodesix; Clovis Oncology; EMD Serono; Lilly; OncoPlex Diagnostics |
Research Funding - Astellas Pharma (Inst); Celgene (Inst); MedImmune (Inst); Merck (Inst); novartis (Inst); Pfizer (Inst) |
|
|
|
Consulting or Advisory Role - ARIAD; Mersana; Novartis; Novartis; Roche |
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Employment - Genentech/Roche; Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Research Funding - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
Other Relationship - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
Research Funding - Pfizer (Inst) |
Patents, Royalties, Other Intellectual Property - Pfizer (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
Honoraria - Celgene; Clovis Oncology; EMD Serono |
Consulting or Advisory Role - Clovis Oncology; EMD Serono |
Research Funding - Celgene; GlaxoSmithKline |